Related Experiment Video
Updated: Aug 7, 2026
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Identification of differentially expressed mRNA transcripts in drug-resistant versus parental human melanoma cell
Nikola Tanic1, Gordana Brkic, Bogomir Dimitrijevic
1Department of Neurobiology and Immunology, Institute of Biological Research "Sinica Stankovic", Belgrade, Israel.
Background:
Malignant melanoma resistance to chemotherapy remains a major limitation to treatment. Our aim was to identify genes associated with drug resistance, in order to better understand the molecular events underlying the drug-resistant phenotype.
Materials And Methods:
A human melanoma cell line and its drug-resistant variants obtained by selection with MNNG or 6-thioguanine were used. Alterations in gene expression were characterized by differential display reverse transcription-polymerase chain reaction (DDRT-PCR). Prominent mRNA fragments present in selected variants and not in the parental cells were identified and characterized by cloning and sequencing. Differential expression was confirmed by real-time RT-PCR.
Results:
Three functionally distinct transcriptional products were demonstrated: the chaperonin subunit TCP 1-zeta-6A (CCT6A), the hyaluronan receptor CD44 and LPPR-2, the lipid phosphate phosphatase-related protein type-2.
Conclusion:
Genes with altered expression were identified in drug-resistant variants. The identified molecules may provide new insights into the molecular basis for melanoma resistance to chemotherapy.
Insights
Researchers identified key genes, including CCT6A, CD44, and LPPR-2, associated with chemotherapy resistance in melanoma. Understanding these genetic changes offers new insights into overcoming drug resistance in malignant melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant melanoma drug resistance is a significant clinical challenge.
- Understanding the molecular basis of this resistance is crucial for developing effective treatments.
Purpose of the Study:
- To identify genes associated with chemotherapy drug resistance in melanoma.
- To elucidate the molecular mechanisms underlying the drug-resistant phenotype.
Main Methods:
- Utilized a human melanoma cell line and its drug-resistant variants.
- Employed differential display reverse transcription-polymerase chain reaction (DDRT-PCR) to detect gene expression alterations.
- Confirmed differential gene expression using real-time RT-PCR.
Main Results:
- Identified three distinct transcriptional products: CCT6A, CD44, and LPPR-2.
- CCT6A is a chaperonin subunit.
- CD44 is a hyaluronan receptor, and LPPR-2 is a lipid phosphate phosphatase-related protein.
Conclusions:
- Successfully identified genes with altered expression in drug-resistant melanoma variants.
- The identified genes (CCT6A, CD44, LPPR-2) may offer novel therapeutic targets.
- These findings provide new insights into the molecular basis of melanoma chemotherapy resistance.
